Currently, there are 100.12M common shares owned by the public and among those 87.84M shares have been available to trade.
Insiders at the company have transacted a total of 6 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 100,000 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 68,099 shares.
The company’s stock has a 5-day price change of 78.50% and 96.74% over the past three months. ADVM shares are trading 153.72% year to date (YTD), with the 12-month market performance up to 173.29% higher. It has a 12-month low price of $0.61 and touched a high of $2.34 over the same period. ADVM has an average intraday trading volume of 494.40K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 102.78%, 118.14%, and 53.58% respectively.
Institutional ownership of Adverum Biotechnologies Inc (NASDAQ: ADVM) shares accounts for 53.85% of the company’s 100.12M shares outstanding.
It has a market capitalization of $192.97M and a beta (3y monthly) value of 0.69. The earnings-per-share (ttm) stands at -$1.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.51% over the week and 11.49% over the month.
Analysts forecast that Adverum Biotechnologies Inc (ADVM) will achieve an EPS of -$0.33 for the current quarter, -$0.28 for the next quarter and -$0.93 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.4 while analysts give the company a high EPS estimate of -$0.27. Comparatively, EPS for the current quarter was -$0.33 a year ago. Earnings per share for the fiscal year are expected to increase by 20.22%, and 25.64% over the next financial year.
Looking at the support for the ADVM, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on July 07, 2022, with the firm’s price target at $4.
